drugset / Trial / NCT06943794
Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial
RandomizedParallel-groupOpen-labelPrevention
Summary
This study is a prospective, multicenter cluster randomized controlled trial. Additional fecal screening for high-risk SNP subtypes, in conjunction with routine Hp testing, may improve the identification of individuals at high risk for gastric cancer. Moreover, the implementation of eradication interventions in high-risk groups has the potential to significantly reduce the incidence and progression of gastric cancer.
Timeline
- Start
- 2026-03-30
- Primary completion
- 2030-05-01
- Completion
- 2030-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bismuth Potassium Citrate | Unknown | 220 mg | — |
| Subject | Esomeprazole | Small molecule | 20 mg | — |
| Subject | Metronidazole | Small molecule | 400 mg | — |
| Subject | Omeprazole | Other / unclassified | 20 mg | — |
| Subject | Tetracycline | Unknown | 500 mg | — |